The Broad Institute will establish a Genome Characterization Center (GCC) to support the Center for Cancer Genomics Pipeline, we propose to build on our 30 year track record as a Genome Center and apply a suite of well-validated platforms and advanced analytic tools to comprehensively characterize genomic alterations of cancer specimens. We will characterize at least 1,200 cancer cases per year as identified by the NCI Center for Cancer Genomics. We will apply DNA-based assays including low coverage whole genome sequencing (WGS), high coverage WGS, whole exome (WEX), targeted panel and methylation-based assays to identify a wide array of types of somatic alterations. We are able to accept and successfully analyze materials from FFPE specimens and have documented extensive experience with this type of sample.